Jasper Therapeutics Reports Promising Briquilimab Study Results

Jasper Therapeutics ( (JSPR) ) has provided an update.

On July 7, 2025, Jasper Therapeutics reported updated data from its BEACON Phase 1b/2a study of briquilimab in adult participants with chronic spontaneous urticaria. The study showed promising results, with 89% of participants in the 240mg and 360mg single-dose cohorts achieving a complete response. However, issues with a specific drug product lot affected results in some cohorts, leading to the halting of the ETESIAN study in asthma and a pause in development for SCID. Jasper plans to enroll additional patients to ensure robust data for future studies and is implementing cost-cutting measures to extend its financial runway.

The most recent analyst rating on (JSPR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).

Average Trading Volume: 251,668

Technical Sentiment Signal: Sell

Current Market Cap: $101.7M

For an in-depth examination of JSPR stock, go to TipRanks’ Overview page.